Postpartum Haemorrhage With Retained PlacentaPhase 2NCT03395730
Intraumbilical Oxytocin Versus Placental Cord Drainage in the Management of 3rd Stage of Labor
A Phase 2 study testing Intraumbilical vein injection oxytocin, placental cord drainage and Expectant managment of 3rd stage of labour in people with Postpartum Haemorrhage With Retained Placenta, run by Eslam Mohammed Abbas at 1 site in Egypt.
Trial summary
The aim of this study is to compare the effectiveness of intraumbilical oxytocin and placental cord drainage in the management of third stage of labor. Does the use of intraumbilical vein oxytocin injection or the use of Placental cord drainage can cause a reduction of blood loss, Hb level drop, the length of the… Read more about this study
- Who is it for?
- Ages 18 to 35 years, women onlyHealthy volunteers can take part
- Conditions the study is for
- Postpartum Haemorrhage With Retained Placenta
- What is being tested?
- Intraumbilical vein injection oxytocin, placental cord drainage and Expectant managment of 3rd stage of labour
- Type of treatment
- Injection or infusion, Surgery or procedure
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 150 participants
- Where
- 1 siteEgypt
- Study dates
- 30 Sep 2017to 30 Jan 2018
- Phase
- Phase 2
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 35 years
- Women only
- Healthy volunteers accepted
- Adult
Who may be able to join
- Pregnant women between 18-35 years of age with normal pregnancy.
- A singleton fetus at a gestational age of 37 - 42 weeks in a cephalic presentation.
- Neonatal birth weight of 2500 to 4500 grams.
Who cannot join
- Medical disorders and hypertensive disorders of pregnancy.
- Intrauterine fetal death.
- Known or suspected fetal anomalies.
- Oxytocin induction or augmented cases.
- Obstetrical complications (bleeding, premature rupture of membranes).
- Previous CS or Previous Myomectomy.
Trial locations and contacts
1 site in 1 country.
Egypt1 site, 1 recruiting
- Recruiting
Ain Shams Maternity Hospital
Cairo, 11311
Tamer F Borg, PHD, 00201001457437, tamerborg1975@gmail.com
Bassem A Islam, PHD, 00201002412634, aly.bassem74@gmail.com
About this study
Official title: Intraumbilical Oxytocin Compared to Placental Cord Drainage in the Management of Third Stage of Labor: A Randomized Controlled Study
The aim of this study is to compare the effectiveness of intraumbilical oxytocin and placental cord drainage in the management of third stage of labor.
Does the use of intraumbilical vein oxytocin injection or the use of Placental cord drainage can cause a reduction of blood loss, Hb level drop, the length of the third stage of labor and the incidence of manual removal of the retained placenta during the third stage of labor in pregnant women after delivery of the infant?
Read the detailed description
Study:
Study Design: A prospective randomized clinical trial. Study setting: The study will be conducted in Ain Shams University Maternity Hospital.
All pregnant women in the delivery ward will be submitted to:
- Detailed complete history taking with special emphasis to maternal age, Parity, Maternal weight, as well as presence of any disease.
- Clinical Examination:
- General examination. b. Abdominal examination (Symphysis-fundal height) and pelvic examination.
- Investigation
- Ultrasound assessment to evaluate GA, fetal weight, AFI and Placental site.
- Basal complete blood picture, urine analysis and random blood sugar. The selected patients will fulfill the following criteria:
- Pregnant women between 18-35 years of age with normal pregnancy.
- A singleton fetus at a gestational age of 37 - 42 weeks in a cephalic presentation.
- Neonatal birth weight of 2500 to 4500 grams. Exclusion criteria:
- Medical disorders and hypertensive disorders of pregnancy.
- Intrauterine fetal death.
- Known or suspected fetal anomalies.
- Oxytocin induction or Augmented cases.
- Obstetrical complications (bleeding, premature rupture of membranes).
- Previous CS or Previous Myomectomy. Study population: The present study will be conducted on 150 women recruited from the delivery ward of our hospital after they had received information on the purpose and course of the study from the medical investigator and had provided the written consent during routine prenatal visits , The 150 study participants will be divided into three groups using simple random distribution technique. After monitoring the duration of active phase and second stage of labor by following the partograph. Randomization and Allocation concealment: Randomization will be based on the sequence generation created by computer and the randomization tables will be kept with the study supervisor. Consenting patients fulfilling inclusion criteria will be randomized into one of the following 3 groups. Randomized allocation will be kept in opaque sealed envelopes, with enrollment numbers written on the envelopes. The envelopes will contain a card on with the designated study group will be written. After enrollment of the patients in the study, the envelopes marked with study number will be unsealed and the patients allocated to either groups:
- Group (A) "Study Group 1": In the labor room women in Group A (n = 50) receive intraumbilical vein injection oxytocin 20 units diluted in 20 ml of 0.9% saline solution immediately after delivery of the baby, clamping and cutting the cord.
- Group (B) "Study Group 2": The women in Group B (n = 50) have placental drainage immediately after delivery. This scenario will include placental cord clamping and cutting after delivery of the baby followed by immediately unclamping of the maternal side, allowing the blood to drain freely for a duration of three minutes.
- Group (C) "Control Group": The women in Group C (n = 50) as a control group receive no intervention. Placenta will be delivered spontaneously after appearance of clinical signs of placental separation, which include strong uterine contraction, vaginal bleeding, and descending of umbilical cord through the vulva. This scenario will include placental cord clamping and cutting after 2 minutes of delivery of the baby. Outcome: Retained placenta is defined as a placenta that remained in the uterus for 30 minutes or more after delivery (Begley et al., 2014).
- 1ry outcome: Duration of the third stage of labor.
- 2ry outcome: Retained placenta, need for manual removal of placenta and the drop in Hb will be recorded. Sample size calculation: Sample size was calculated using PASS® version 11 program, sample size calculation was based on study carried out by (Güngördük et al., 2011). A preliminary power analysis was carried out to calculate the sample size using a formula: d = Δ/SD, where d is standardized difference, Δ is the smallest clinically significant difference and SD is standard deviation of the test group. Duration of 1.6 minutes was considered as the smallest clinically significant difference, and the SD (1.6 minutes) was selected the study performed by (Güngördük et al., 2011). Also, a standardized difference of 1.0 was obtained using nomogram. The power analysis suggested that a sample of 50 women in each group would provide a power of 95%, at 5% significance.
- Being tested
- Intraumbilical vein injection oxytocin, placental cord drainage, Expectant managment of 3rd stage of labour
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Intraumbilical vein injection oxytocinDrug
intraumbilical vein injection of oxytocin 20 units diluted in 20 ml of 0.9% saline solution immediately after delivery of the baby, clamping and cutting the cord.
placental cord drainageProcedure or surgery
placental cor drainage immediately after delivery. This scenario will include placental cord clamping and cutting after delivery of the baby followed by immediately unclamping of the maternal side, allowing the blood to drain freely for a duration of three minutes.
Expectant managment of 3rd stage of labourProcedure or surgery
Placenta will be delivered spontaneously after appearance of clinical signs of placental separation, which include strong uterine contraction, vaginal bleeding, and descending of umbilical cord through the vulva. This scenario will include placental cord clamping and cutting after 2 minutes of delivery of the baby.
| Study group | Role | What they receive |
|---|---|---|
| • Group (A) "Study Group 1": | Experimental | In the labor room women in Group A (n = 50):
* Clamping and cutting the placental cord after delivery of the baby.
* Immediate intraumbilical vein injection of Oxytocin (Syntocinon®) 20 units diluted in 20 ml of 0.9% saline solution Receives: Drug: Intraumbilical vein injection oxytocin |
| • Group (B) "Study Group 2": | Experimental | In the labor room women in Group B (n = 50):
* Clamping and cutting the placental cord after delivery of the baby.
* Immediate unclamping of the maternal side, allowing the blood to drain freely for a duration of three minutes. Receives: Procedure: placental cord drainage |
| • Group (C) "Control Group": | Active comparator | In the labor room women in Group C (n = 50):
* Clamping and cutting the placental cord after 2 minutes of delivery of the baby.
* Placenta will be delivered spontaneously after appearance of clinical signs of placental separation Receives: Procedure: Expectant managment of 3rd stage of labour |
What is being measured
The primary outcome is the main question the study is designed to answer.
Duration of the third stage of labor.
Duration of placental expulsion from the uterus after delivery of the fetus. by the use of a stop watch to calculate the time in minutes and seconds passing starting from the delivery of the baby till delivery of the placenta outside the the vagina.
To compare How long does the 3rd stage of labor persist with each intervention (in minutes and seconds).
Measured: 5-15 minutes
Secondary outcomes (3)
Retained placenta
defined as a placenta that remained in the uterus for 30 minutes or more after delivery.
by the use of a stop watch to calculate the time in minutes and seconds needed for placental expulsion.
To compare which intervention can result in delayed expulsion of placenta (in minutes and seconds) and cause a retained placenta.
Measured: >30 minutes
the Need for manual removal of placenta
manual removal of the placenta under general anesthesia if the placental expulsion is delayed for more than 30 minutes.
to compare which intervention will require manual removal of the retained(by the percentage of yes and no) placenta.
Measured: > 30 minutes
the drop in hemoglobin in gm/dl
hemoglobin concentration in gm/dl will be measured for all participants before onset of delivery of the baby and 2 hours after labour and compare which maneuver included increased blood loss determined by the difference of hemoglobin concentration in gm/dl in the basal Hb level and the 2hr later Hb level.
Measured: after 2 hours
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted10 Jan 2018
- Study start30 Sep 2017
- Primary completion15 Jan 2018 (estimated)
- Study completion30 Jan 2018 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Postpartum Haemorrhage With Retained PlacentaStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 2
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- The present study will be conducted on 150 women recruited from the delivery ward of our hospital after they had received information on the purpose and course of the study from the medical investigator and had provided the written consent during routine prenatal visits , they will be randomly divided into: * Group (A) "Study Group 1": (n = 50) * Group (B) "Study Group 2": (n = 50) * Group (C) "Control Group": (n = 50)
- Masking
- Double blind
- Who is masked
- Participant, Care provider
- Enrolment
- 150 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Eslam Mohammed Abbas
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor-investigator, Eslam Mohammed Abbas, Ain Shams University
- Investigators
- Tamer F Borg, MD, Study director, Ain Shams UniversityBassem I Ali, MD, Study director, Ain Shams UniversityIslam M Abbas, MBBch, Principal investigator, Ain Shams University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03395730
- Sponsor's protocol ID
- ppsi
- Status last verified
- Jan 2018
- First submitted
- 28 Dec 2017
- Last updated
- 10 Jan 2018
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
- Individual data sharing
- Yes
Study at a glance
From the registry record, last updated by the sponsor on 10 Jan 2018. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Intraumbilical Oxytocin Compared to Placental Cord Drainage in the Management of Third Stage of Labor: A Randomized Controlled Study
- ClinicalTrials.gov ID
- NCT03395730
- Acronym / sponsor ID
- ppsi
- Phase
- Phase 2
- Study type
- Interventional
- Recruitment status
- Unknown status
- Enrolment
- 150 participants (estimated)
- Lead sponsor
- Eslam Mohammed AbbasUniversity, hospital or other
- Study start
- 30 Sep 2017 (actual)
- Primary completion
- 15 Jan 2018 (estimated)
- Study completion
- 30 Jan 2018 (estimated)
- First posted
- 10 Jan 2018 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The aim of this study is to compare the effectiveness of intraumbilical oxytocin and placental cord drainage in the management of third stage of labor.
Does the use of intraumbilical vein oxytocin injection or the use of Placental cord drainage can cause a reduction of blood loss, Hb level drop, the length of the third stage of labor and the incidence of manual removal of the retained placenta during the third stage of labor in pregnant women after delivery of the infant?
Detailed description
Study:
Study Design: A prospective randomized clinical trial. Study setting: The study will be conducted in Ain Shams University Maternity Hospital.
All pregnant women in the delivery ward will be submitted to:
- Detailed complete history taking with special emphasis to maternal age, Parity, Maternal weight, as well as presence of any disease.
- Clinical Examination:
- General examination. b. Abdominal examination (Symphysis-fundal height) and pelvic examination.
- Investigation
- Ultrasound assessment to evaluate GA, fetal weight, AFI and Placental site.
- Basal complete blood picture, urine analysis and random blood sugar. The selected patients will fulfill the following criteria:
- Pregnant women between 18-35 years of age with normal pregnancy.
- A singleton fetus at a gestational age of 37 - 42 weeks in a cephalic presentation.
- Neonatal birth weight of 2500 to 4500 grams. Exclusion criteria:
- Medical disorders and hypertensive disorders of pregnancy.
- Intrauterine fetal death.
- Known or suspected fetal anomalies.
- Oxytocin induction or Augmented cases.
- Obstetrical complications (bleeding, premature rupture of membranes).
- Previous CS or Previous Myomectomy. Study population: The present study will be conducted on 150 women recruited from the delivery ward of our hospital after they had received information on the purpose and course of the study from the medical investigator and had provided the written consent during routine prenatal visits , The 150 study participants will be divided into three groups using simple random distribution technique. After monitoring the duration of active phase and second stage of labor by following the partograph. Randomization and Allocation concealment: Randomization will be based on the sequence generation created by computer and the randomization tables will be kept with the study supervisor. Consenting patients fulfilling inclusion criteria will be randomized into one of the following 3 groups. Randomized allocation will be kept in opaque sealed envelopes, with enrollment numbers written on the envelopes. The envelopes will contain a card on with the designated study group will be written. After enrollment of the patients in the study, the envelopes marked with study number will be unsealed and the patients allocated to either groups:
- Group (A) "Study Group 1": In the labor room women in Group A (n = 50) receive intraumbilical vein injection oxytocin 20 units diluted in 20 ml of 0.9% saline solution immediately after delivery of the baby, clamping and cutting the cord.
- Group (B) "Study Group 2": The women in Group B (n = 50) have placental drainage immediately after delivery. This scenario will include placental cord clamping and cutting after delivery of the baby followed by immediately unclamping of the maternal side, allowing the blood to drain freely for a duration of three minutes.
- Group (C) "Control Group": The women in Group C (n = 50) as a control group receive no intervention. Placenta will be delivered spontaneously after appearance of clinical signs of placental separation, which include strong uterine contraction, vaginal bleeding, and descending of umbilical cord through the vulva. This scenario will include placental cord clamping and cutting after 2 minutes of delivery of the baby. Outcome: Retained placenta is defined as a placenta that remained in the uterus for 30 minutes or more after delivery (Begley et al., 2014).
- 1ry outcome: Duration of the third stage of labor.
- 2ry outcome: Retained placenta, need for manual removal of placenta and the drop in Hb will be recorded. Sample size calculation: Sample size was calculated using PASS® version 11 program, sample size calculation was based on study carried out by (Güngördük et al., 2011). A preliminary power analysis was carried out to calculate the sample size using a formula: d = Δ/SD, where d is standardized difference, Δ is the smallest clinically significant difference and SD is standard deviation of the test group. Duration of 1.6 minutes was considered as the smallest clinically significant difference, and the SD (1.6 minutes) was selected the study performed by (Güngördük et al., 2011). Also, a standardized difference of 1.0 was obtained using nomogram. The power analysis suggested that a sample of 50 women in each group would provide a power of 95%, at 5% significance.
Study design
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (participant, care provider)
- Number of arms
- 3
- Model description
- The present study will be conducted on 150 women recruited from the delivery ward of our hospital after they had received information on the purpose and course of the study from the medical investigator and had provided the written consent during routine prenatal visits , they will be randomly divided into: * Group (A) "Study Group 1": (n = 50) * Group (B) "Study Group 2": (n = 50) * Group (C) "Control Group": (n = 50)
| Arm | Type | Receives |
|---|---|---|
| • Group (A) "Study Group 1": | Experimental | Drug: Intraumbilical vein injection oxytocinIn the labor room women in Group A (n = 50): * Clamping and cutting the placental cord after delivery of the baby. * Immediate intraumbilical vein injection of Oxytocin (Syntocinon®) 20 units diluted in 20 ml of 0.9% saline solution |
| • Group (B) "Study Group 2": | Experimental | Procedure: placental cord drainageIn the labor room women in Group B (n = 50): * Clamping and cutting the placental cord after delivery of the baby. * Immediate unclamping of the maternal side, allowing the blood to drain freely for a duration of three minutes. |
| • Group (C) "Control Group": | Active comparator | Procedure: Expectant managment of 3rd stage of labourIn the labor room women in Group C (n = 50): * Clamping and cutting the placental cord after 2 minutes of delivery of the baby. * Placenta will be delivered spontaneously after appearance of clinical signs of placental separation |
Who may qualify
- Ages
- 18 to 35 years
- Sex
- Female only
- Healthy volunteers
- Accepted
- Age groups
- Adult
Key inclusion criteria (3 listed)
- Pregnant women between 18-35 years of age with normal pregnancy.
- A singleton fetus at a gestational age of 37 - 42 weeks in a cephalic presentation.
- Neonatal birth weight of 2500 to 4500 grams.
Key exclusion criteria (6 listed)
- Medical disorders and hypertensive disorders of pregnancy.
- Intrauterine fetal death.
- Known or suspected fetal anomalies.
- Oxytocin induction or augmented cases.
- Obstetrical complications (bleeding, premature rupture of membranes).
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Intraumbilical vein injection oxytocinintraumbilical vein injection of oxytocin 20 units diluted in 20 ml of 0.9% saline solution immediately after delivery of the baby, clamping and cutting the cord. | Drug | • Group (A) "Study Group 1": |
| placental cord drainageplacental cor drainage immediately after delivery. This scenario will include placental cord clamping and cutting after delivery of the baby followed by immediately unclamping of the maternal side, allowing the blood to drain freely for a duration of three minutes. | Procedure or surgery | • Group (B) "Study Group 2": |
| Expectant managment of 3rd stage of labourPlacenta will be delivered spontaneously after appearance of clinical signs of placental separation, which include strong uterine contraction, vaginal bleeding, and descending of umbilical cord through the vulva. This scenario will include placental cord clamping and cutting after 2 minutes of delivery of the baby. | Procedure or surgery | • Group (C) "Control Group": |
Primary outcome
Duration of the third stage of labor.
Time frame: 5-15 minutes
Duration of placental expulsion from the uterus after delivery of the fetus. by the use of a stop watch to calculate the time in minutes and seconds passing starting from the delivery of the baby till delivery of the placenta outside the the vagina. To compare How long does the 3rd stage of labor persist with each intervention (in minutes and seconds).
3 secondary outcomes
Retained placenta
Time frame: >30 minutes
the Need for manual removal of placenta
Time frame: > 30 minutes
the drop in hemoglobin in gm/dl
Time frame: after 2 hours
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 10 Jan 2018.
- Individual participant dataSharing planned: Yes
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Tamer F Borg, MD study director
Ain Shams University
Bassem I Ali, MD study director
Ain Shams University
Islam M Abbas, MBBch principal investigator
Ain Shams University
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 2 study testing Intraumbilical vein injection oxytocin, placental cord drainage and Expectant managment of 3rd stage of labour in people with Postpartum Haemorrhage With Retained Placenta, run by Eslam Mohammed Abbas at 1 site in Egypt.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 10 Jan 2018. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact Islam M Abbas, MBBch (00201025864906, dr.eslamabbas@gmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Duration of the third stage of labor. (time frame: 5-15 minutes). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 10 Jan 2018.